Chart-Typ:
Zeitraum:
| Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome | MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced... ► Artikel lesen |
| Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals | BOTHELL, Wash. & MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
